BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3140887)

  • 21. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
    Grönberg A; Ferm M; Tsai L; Kiessling R
    Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
    Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
    J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia.
    Bigda J; Mysliwska J; Baran W; Hellmann A; Mysliwski A
    Leuk Lymphoma; 1993 Mar; 9(4-5):371-6. PubMed ID: 8348073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.
    Ostensen ME; Thiele DL; Lipsky PE
    J Biol Response Mod; 1989 Feb; 8(1):53-61. PubMed ID: 2493514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
    Djeu JY; Blanchard DK
    Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.
    Maio M; Altomonte M; Tatake R; Zeff RA; Ferrone S
    J Clin Invest; 1991 Jul; 88(1):282-9. PubMed ID: 1905328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hairy cell leukemia cells are relatively NK-insensitive targets.
    Starling GC; Nimmo JC; Hart DN
    Pathology; 1988 Oct; 20(4):361-5. PubMed ID: 2977221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
    Sone S; Utsugi T; Nii A; Ogura T
    J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
    Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
    J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
    Brooks B; Chapman K; Lawry J; Meager A; Rees RC
    Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
    Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
    Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-induced resistance of tumor target cells against lysis by interleukin-2-activated killer cells.
    Takagi S; Minakuchi J; Okawa H; Yata J
    Tohoku J Exp Med; 1989 Feb; 157(2):131-6. PubMed ID: 2496486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.